pc14586
pmv pharmaceuticals
['solid tumor', 'pc14586 ']
 is pleased to announce initial pc14586 phase 1 data presented at asco demonstrated anti-tumor activity across multiple solid tumor types with a p53 y220c mutation. read the full press release here: #oncology #asco22 
PMV Pharma is developing first-in-class p53 reactivators for the treatment  of cancer.